Hematologic Malignancy
Diffuse Large B-Cell Lymphoma
CI-CAN-00005107DLBCLExplore in graph →
Hematologic355 active trials5 approved drugs19 evidence items
- NCIt
- C8851
- DOID
- 0050745
- Other
- 4 more codes
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005107DLBCLExplore in graph →
Clinical trials
1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02753062 | Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma(PTLD) | unknown | Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT02388581 | First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL | unknown | Phase 2 | 30 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT01949818 | Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 4 | 120 | Mingzhi ZhangOTHER | 1 | Dec 30, 2015 | clinicaltrials |
| NCT02449265 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 160 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT02449278 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | unknown | Phase 3 | 120 | Wuhan UniversityOTHER | 1 | Dec 14, 2015 | clinicaltrials |
| NCT01793844 | A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients | unknown | — | 732 | Sun Yat-sen UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT02531841 | High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma(MATRix) | unknown | Phase 3 | 250 | University Hospital FreiburgOTHER | 1 | Aug 25, 2015 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT01990144 | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01865058 | The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma. | unknown | — | 50 | Odense University HospitalOTHER | 1 | May 30, 2013 | clinicaltrials |
| NCT01278602 | R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma | unknown | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | unknown | Phase 2 | 196 | Fudan UniversityOTHER | 1 | Mar 5, 2013 | clinicaltrials |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | unknown | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 13, 2011 | clinicaltrials |
| NCT00846157 | Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients(NKCell) | unknown | Phase 3 | 276 | NKBio Co.Ltd.INDUSTRY | 1 | Jun 28, 2011 | clinicaltrials |
| NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma(DLCL04) | unknown | Phase 3 | 399 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT01066429 | DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Hospital Universitario Principe de AsturiasOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00333008 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | unknown | Phase 2 | 27 | The Alvin and Lois Lapidus Cancer InstituteOTHER | 1 | Sep 26, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Apr 27, 2016source: clinicaltrials